Novavax is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. Novavax's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus, seasonal influenza, pandemic influenza and the Ebola virus.

Type
Public
HQ
Gaithersburg, US
Founded
1987
Size (employees)
355 (est)
Novavax was founded in 1987 and is headquartered in Gaithersburg, US
Report incorrect company information

Novavax Office Locations

Novavax has offices in Gaithersburg, Rockville and Uppsala
Gaithersburg, US (HQ)
20 Firstfield Rd
Rockville, US
9920 Belward Campus Dr
Uppsala, SE
109 Kungsgatan
Show all (3)
Report incorrect company information

Novavax Financials and Metrics

Novavax Financials

Novavax's revenue was reported to be $31.18 m in FY, 2017
USD

Revenue (Q1, 2018)

9.7 m

Net income (Q1, 2018)

(46.4 m)

EBIT (Q1, 2018)

(43.5 m)

Market capitalization (14-Jun-2018)

618.3 m

Closing share price (14-Jun-2018)

1.6

Cash (31-Mar-2018)

113.4 m

EV

823 m
Novavax's current market capitalization is $618.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

20.9 m30.7 m36.3 m15.4 m31.2 m

Revenue growth, %

(5%)47%18%(58%)

General and administrative expense

14.8 m19.9 m30.8 m46.5 m34.5 m

R&D expense

50.3 m79.4 m162.6 m237.9 m168.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

4.8 m7.5 m8.3 m8.2 m9.9 m14 m6.5 m4.2 m2.5 m3.2 m5.7 m6.7 m9.7 m

General and administrative expense

3.9 m4.3 m5.8 m4.8 m5.8 m7.1 m9.1 m10.5 m14.1 m13.6 m8.9 m8.9 m8.7 m

R&D expense

13.9 m14.5 m15.2 m19.2 m25.9 m25 m27.9 m69 m64.9 m53 m37.7 m39.3 m44.5 m

Operating expense total

20.1 m21.8 m26.1 m28 m34.2 m34.8 m39.7 m79.5 m79 m66.5 m46.5 m48.2 m53.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

119.5 m32.3 m93.1 m144.4 m106.3 m

Accounts Receivable

1.9 m7.5 m2.3 m233 k

Inventories

9.2 m19.3 m21.8 m

Current Assets

145 m188.2 m287.3 m287.8 m203.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

122.5 m109.9 m103.9 m34.5 m215.1 m167.4 m138.1 m132.2 m89.4 m119.9 m95.8 m75.8 m113.4 m

Accounts Receivable

4.5 m406 k363 k591 k

Current Assets

155 m128.9 m166.6 m192 m350.1 m333 m310.1 m484.6 m420 m353.9 m258.4 m236.7 m181 m

PP&E

14 m14.3 m15.1 m17.5 m24 m26.1 m29.4 m36.6 m39.7 m41 m39.4 m38.5 m32.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(52 m)(82.9 m)(156.9 m)(280 m)(183.8 m)

Depreciation and Amortization

2.6 m4.4 m6 m8.5 m9.8 m

Accounts Payable

4.2 m14 m9.1 m(4.8 m)5.2 m

Cash From Operating Activities

(45.4 m)(87.1 m)60.8 m(255.5 m)(138.7 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(37.9 m)(13.8 m)(31.7 m)(51.4 m)(24.4 m)(45 m)(78.1 m)(77.3 m)(156.6 m)(222.9 m)(43.9 m)(88.3 m)(46.4 m)

Depreciation and Amortization

1.6 m980 k2 m3 m1.3 m2.8 m4.3 m2 m4.1 m6.3 m2.1 m4.2 m2.1 m

Accounts Payable

623 k(4 m)(1.3 m)(164 k)(7.6 m)(8.3 m)(7.7 m)1.5 m9 m6.4 m(4.9 m)(105 k)(13.3 m)

Cash From Operating Activities

(33.1 m)(20.4 m)(31.4 m)(47.2 m)(30.5 m)(42.8 m)(71.3 m)(69.8 m)(131.9 m)(194.2 m)(38.6 m)(69.4 m)(66.1 m)
USDY, 2018

EV/EBIT

-18.9 x

EV/CFO

-12.5 x

EV/FCF

-12.4 x

Revenue/Employee

27.2 k

Financial Leverage

-2.8 x
Show all financial metrics

Novavax Operating Metrics

FY, 2016

Phase I Trials Products

2

Phase II Trials Products

1

Phase III Trials Products

1

Preclinical Phase Products

3
Show all operating metrics
Report incorrect company information

Novavax Online and Social Media Presence

Embed Graph
Report incorrect company information